An enzyme immunoassay for determining 17α-hydroxyprogesterone in dried blood spots on filter paper using an ultramicroanalytical system

Clinica Chimica Acta

Volumn 394, Issue 1-2, 2008, Pages 63-66

  González, Ernesto Carlos ^a   Marrero, Neivis ^a   Pérez, Pedro Lucio ^a   Frómeta, Amarilys ^a   Zulueta, Orlando ^a   Herrera, Darlenis ^a   Martínez, Luisa ^a   Castells, Elisa ^a  

^a Immunoassay Center Cuba   (Cuba)

Author keywords

17 OHP; Blood spots; Congenital adrenal hyperplasia; Newborn screening; UltramicroELISA

Indexed keywords

ALKALINE PHOSPHATASE; DANAZOL; HYDROXYPROGESTERONE; POLYCLONAL ANTIBODY; RABBIT ANTISERUM; STEROID BINDING PROTEIN;

ARTICLE; BINDING SITE; BLOOD; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH PROGRAM; HUMAN; HUMAN CELL; MICROANALYSIS; NEWBORN SCREENING; PAPER; PRIORITY JOURNAL;

17-ALPHA-HYDROXYPROGESTERONE; ANTIBODY SPECIFICITY; CROSS REACTIONS; HUMANS; IMMUNOENZYME TECHNIQUES; MICROCHEMISTRY; MICROPORE FILTERS;

ORYCTOLAGUS CUNICULUS;

EID: 44649178558     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2008.04.004     Document Type: Article

References (24)

1. New M.I., and Wilson R.C. Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess. Proc Natl Acad Sci U S A 96 (1999) 12790-12797
2. Pang S., Wallace M.A., Hofman L., and Thuline H.C. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatr 81 (1988) 866-874
3. Levine L.S. Congenital adrenal hyperplasia. Pediatr Rev 21 5 (2000) 159-170
4. Larsson A., Hagenfeldt L., Von Dobeln V., Gustaffson J., and Svensson E. Neonatal screening for congenital adrenal hyperplasia using 17- hydroxyprogesterone assay in filter paper blood spots. Horm Res 30 (1988) 235-240
5. Torresani T., Grüters A., Scherz R., Burckhardt J.J., Harras A., and Zachmann M. Improving the efficacy of newborn screening for congenital adrenal hyperplasia by adjusting the cut-off level of 17α-hydroxyprogesterone to gestational age. Screening 3 (1994) 77-84
6. Pang S., Hotchkiss J., Drash A.L., Levine L.S., and New M.I. Microfilter paper method for 17 alpha-hydroxyprogesterone radioimmunoassay its application for rapid screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 45 (1977) 1003-1008
7. Pang S., and Clark A. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: newborn screening and its relationship to the diagnosis and treatment of the disorder. Screening 2 (1993) 105-139
8. Pang S., and Shook M.K. Current status of neonatal screening for congenital adrenal hyperplasia. Curr Opin Pediatr 9 (1997) 419-423
9. González R.R., Mäentausta O., Solyom J., and Vihko R. Direct solid-phase time-resolved fluoroimmunoassay of 17α-hydroxyprogesterone in serum and dried blood spots on filter paper. Clin Chem 36 9 (1990) 1667-1672
10. National Research Council; Commission of Life Sciences. Institute of laboratory animals resources. Guide for the care and use of laboratory animals (1996), National Academy Press, Washington D.C.
11. Marrero N., Zulueta O., González E.C., Montalvo G., Pérez P.L., and Melchor A. Obtention of 17α-hydroxyprogesterone/alkaline phosphatase conjugates for use in the diagnosis of congenital adrenal hyperplasia. CENIC 34 1 (2003) 23-28
12. Lin L.I. A concordance correlation coefficient to evaluate reproducibility. Biometrics 45 (1989) 255-268
13. CLSI. Protocols for determination of limits of detection and limits of quantitation; approvedguideline. CLSI document EP17-A (2004), Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA 19087-1898
14. Wild D. The immunoassay handbook (1994), MacMillan 83-100
15. Abraham G.E. Solid-phase radioimmunoassay of estradiol-17b. J Clin Endocrinol Metab 29 (1969) 866-870
16. 125I radioimmunoassay for 17α-hydroxyprogesterone in plasma, for diagnosing and managing congenital adrenal hyperplasia. Clin Chem 31 3 (1985) 454-456
17. Maeda M., Arakawa H., Tsuji A., et al. Enzyme-linked immunosorbent assay for 17α-hydroxyprogesterone in dried blood spotted on filter paper. Clin Chem 33 6 (1987) 761-764
18. Gruñeiro de Papendieck L., Prieto L., Chiesa A., Bengolea S., and Bergadá C. Congenital adrenal hyperplasia and early newborn screening:17α-hydroxyprogesterone (17α-OHP) during the first days of life. J Med Screen 5 (1998) 24-26
19. Cavarzere P., Camilot M., Teofoli F., and Tató L. Neonatal screening for congenital adrenal hyperplasia in North-Eastern Italy: a report three years into the program. Horm Res 63 (2005) 180-186
20. Wallace A.M., Beastall, Cook B., et al. Neonatal screening for congenital adrenal hyperplasia: a programme based on a novel direct radioimmunoassay for 17-hydroxyprogesterone in blood spots. J Endocr 108 (1986) 299-308
21. Linder N., Davidovitch N., Kogan A., et al. Longitudinal measurements of 17α-hydroxyprogesterone in premature infants during the first three months of life. Arch Dis Child Fetal Neonatal Ed 81 (1999) 175-178
22. Nordenström A., Wedell A., Hagenfeldt L., Marcus C., and Larsson A. Neonatal screening for congenital adrenal hyperplasia:17 hidroxyprogesterone levels and CYP21 genotypes in preterm infants. Pediatrics 108 (2001) E68
23. Olgemöller B., Roscher A.A., Liebl B., and Fingerhut R. Screening for congenital adrenal hyperplasia: adjustment of 17-hydroxyprogesterone cut-off values to both age and birth >weight markedly improves the predictive value. J Clin Endocrinol Metab 88 (2003) 5790-5794
24. Van der Kamp H.J., Oudshoorn C.G.M., Elvers B.H., et al. Cut-off levels of 17-alpha-hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight. J Clin Endocrinol Metab 90 (2005) 3904-3907